Can AI Save Pfizer Stock Before Its Patent Cliff Hits?
Management’s story has pivoted from concrete wins today to a distant, AI-powered future, a move that coincides with…
How Much Upside Is Left in JNJ Stock?
While the market fixates on the STELARA patent cliff, the rest of the story is being missed. That…
Can Cost Cuts And 2030 Targets Really Save Pfizer Stock?
The company now leads with a cost-savings total and a growth rate that does not begin until the…
Can Eli Lilly Stock Keep Surging As Drug Prices Fall?
The past year’s gain was bought with volume and access, and management has already said net price goes…
Eli Lilly Found a New Gear. You Paid For It.
Beyond strong drugs, the stock’s ascent was powered by its notable profitability. You watched Eli Lilly (LLY) climb…
Pfizer Stock Is A Race Between New Drugs And Old Patents
The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its…
Why Isn’t Eli Lilly Stock Trading At The Top Of Its Peer Group?
The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group’s…
The Signs Before Eli Lilly Stock Surged Were All On The Record
Eli Lilly stock ran on a story that was public and dated long before the price moved, and…
How Does LLY Stock Reach $2,100?
At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years…
Everyone Is Watching Eli Lilly Stock’s New Drugs. Here Is the Metric That Vanished
Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how…
The Catch Hiding In Eli Lilly Stock’s Growth Story
Eli Lilly’s obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on…
Pfizer, YaoPharma sign $150M GLP-1 obesity drug collaboration
Key Terms phase 1 medical Phase 1 is the first stage of testing…